BACKGROUND: Women ≥70 years old with clinically (c) lymph node (LN) negative (-), hormone receptor (HR) positive (+) breast cancer are recommended not to be routinely staged with a sentinel LN biopsy. We sought to determine how this affects adjuvant decision-making. METHODS: Statistical analyses were performed to determine the association of LN evaluation with adjuvant chemotherapy and radiation therapy in cLN-, HR + breast cancer patients in the National Cancer Database. RESULTS: Between 2004 and 2013, there were 193,728 patients aged 70-90 with cLN-, HR + breast cancer; 15.0% were LN+. LN + patients were more likely to receive chemotherapy (28.3% vs. 5.5%, p < 0.001), hormonal therapy (83.6% vs. 71.4%, p < 0.001), post-lumpectomy radiation therapy (81.4% vs. 73.6%, p < 0.001) and post-mastectomy radiation therapy (30.3% vs. 5.1%, p < 0.001). CONCLUSION: 15% of patients aged 70-90 will be LN+. These patients more frequently receive systemic and radiation therapy. LN status may affect treatment in these patients.
BACKGROUND:Women ≥70 years old with clinically (c) lymph node (LN) negative (-), hormone receptor (HR) positive (+) breast cancer are recommended not to be routinely staged with a sentinel LN biopsy. We sought to determine how this affects adjuvant decision-making. METHODS: Statistical analyses were performed to determine the association of LN evaluation with adjuvant chemotherapy and radiation therapy in cLN-, HR + breast cancerpatients in the National Cancer Database. RESULTS: Between 2004 and 2013, there were 193,728 patients aged 70-90 with cLN-, HR + breast cancer; 15.0% were LN+. LN + patients were more likely to receive chemotherapy (28.3% vs. 5.5%, p < 0.001), hormonal therapy (83.6% vs. 71.4%, p < 0.001), post-lumpectomy radiation therapy (81.4% vs. 73.6%, p < 0.001) and post-mastectomy radiation therapy (30.3% vs. 5.1%, p < 0.001). CONCLUSION: 15% of patients aged 70-90 will be LN+. These patients more frequently receive systemic and radiation therapy. LN status may affect treatment in these patients.
Authors: Brooke C Bredbeck; Nicole M Mott; Ton Wang; Brandy R Sinco; Tasha M Hughes; Hari Nathan; Lesly A Dossett Journal: Ann Surg Oncol Date: 2022-04-05 Impact factor: 5.344
Authors: Lesly A Dossett; Nicole M Mott; Brooke C Bredbeck; Ton Wang; Chad Tc Jobin; Tasha M Hughes; Sarah T Hawley; Brian J Zikmund-Fisher Journal: J Surg Res Date: 2021-11-19 Impact factor: 2.192
Authors: Matthew Castelo; Justin Lu; Lawrence Paszat; Zachary Veitch; Kuan Liu; Adena S Scheer Journal: Breast Cancer Res Treat Date: 2022-06-22 Impact factor: 4.624
Authors: Nicole Mott; Ton Wang; Jacquelyn Miller; Nicholas L Berlin; Sarah Hawley; Reshma Jagsi; Brian J Zikmund-Fisher; Lesly A Dossett Journal: Ann Surg Oncol Date: 2020-07-27 Impact factor: 5.344
Authors: Ton Wang; Alison Baskin; Jacquelyn Miller; Allan Metz; Niki Matusko; Tasha Hughes; Michael Sabel; Jacqueline S Jeruss; Lesly A Dossett Journal: Ann Surg Oncol Date: 2020-07-10 Impact factor: 5.344
Authors: Ton Wang; Nicole Mott; Jacquelyn Miller; Nicholas L Berlin; Sarah Hawley; Reshma Jagsi; Lesly A Dossett Journal: JAMA Netw Open Date: 2020-09-01